ALX2004 is a potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors that was created from ALX Oncology’s proprietary linker-payload ...

1Department of Pathology, Yale University School of Medicine, New Haven, Connecticut. 2Department of Internal Medicine, National and Kapodistrian University of Athens, School of Medicine, Sotiria ...

The availability of MSD’s vaccine in individual nations will be subject to various factors. Credit: Copyright © 2025 Merck & Co., Inc., Rahway, NJ, USA and its ...